UiPath Q2 Results Beat Street View, But Shares Down 7%

Shares of UiPath Inc. (PATH) slipped over 7% in extended trading session Tuesday despite the robotic process automation solutions provider's second-quarter results beating Wall Street view.

The company reported second-quarter net loss of $100.0 million or $0.19 per share, compared to last year's profit of $5.0 million or break even per share.

On an adjusted basis, UiPath reported earnings of $0.01 per share, down from $0.03 per share last year. Analysts polled by Thomson Reuters expected a loss of $0.05 per share for the quarter. Analysts' estimates typically exclude one-time items.

Revenues for the second quarter rose 40% to $195.5 million from $139.4 million last year. Analysts had a consensus revenue estimate of $184.34 million for the quarter.

"We continued our very strong momentum in the second quarter of fiscal year 2022 with ARR growing 60 percent year-over-year to $726.5 million. Our results were driven by both new customer additions, ending the quarter with more than 9,100 customers, as well as robust expansion with existing customers, reflected in our best-in-class dollar-based net retention rate of 144 percent," said CEO Daniel Dines.

Looking forward the third quarter, UiPath expects annualized renewal run rate or ARR of $796 million and $798 million and revenues of $207 million and $209 million. Analysts currently estimate revenues of $206.17 million for the quarter.

For the full year 2022, UiPath expects ARR of $876 million and $881 million.

ARR is a metric used to predict the financial performance of SaaS company over the coming year based on past earnings data.

PATH closed Tuesday's trading at $62.46, down $0.91 or 1.44%, on the Nasdaq. The stock further slipped $4.71 or 7.54% in the after-hours trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Frozen Food Development is recalling specific lots of Lidl branded 12-ounce packages of Frozen Chopped Spinach citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The product comes in 12-ounce poly bags, and items included in the recall are marked with lot # R17742 or R17963 on the back of the poly bag with a best by date of 09/10/23. Starbucks has dropped its vaccine or weekly test requirement against Covid-19 for U.S. employees in the wake of last week's U.S. Supreme Court ruling. The court, in a 6-3 vote, has blocked President Joe Biden's vaccine-or-test mandate for private companies with 100 or more employees. However, it allowed the vaccine mandate to stand for certain health care workers. Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling one batch of its non-interchangeable Semglee (insulin glargine injection), 100 units/ml (U-100), 3mL prefilled pens due to the potential for a missing label, the U.S. Food and Drug Administration said.
Follow RTT